June 4, 2026 · Form 4 insider transaction
Molineaux Christopher P. bought 10,987 shares of Aclaris Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.; The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.; This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.